“`html
Study Summary: Impact of Allogeneic Hematopoietic Cell Transplantation on Patients with FLT3-ITDmut+ AML
Background
Allogeneic hematopoietic cell transplantation (alloHCT) is used to treat patients with acute myeloid leukemia (AML) with FLT3-ITD mutation, but the impact of different characteristics on outcomes after transplant is not fully understood.
Objective
To determine the impact of patient, disease, and transplant characteristics on clinical outcomes and trends in maintenance therapy for patients with FLT3-ITDmut+ AML who underwent their first alloHCT.
Study Design
- Observational cohort study of adult recipients of alloHCT in the US and Canada (2014‒2019)
- Data collected from CIBMTR
- Excluded patients in the MORPHO clinical trial (NCT02997202)
- Primary endpoints: overall survival (OS) and leukemia-free survival (LFS)
- Key secondary endpoints: relapse after alloHCT, non-relapse mortality (NRM), time from diagnosis to complete remission, time from complete remission to alloHCT, and maintenance therapy before and after alloHCT
Results
A total of 3147 eligible patients were included, with most characteristics being similar between different disease statuses. Patients in CR1 status had significantly improved OS and LFS compared to those in CR2 or R/R status. Disease status was associated with relapse and NRM. Maintenance therapy usage after alloHCT increased from 2014 to 2019, primarily due to increased FLT3 inhibitor use.
Conclusion
Disease status of CR1 at the time of alloHCT was associated with better clinical outcomes. Additional factors were identified that may also impact clinical outcomes, providing valuable information for clinical decision-making.
“`
